

RNA PRIME—Harnessing tumor RNA for Immunotherapy against Osteosarcoma

John Ligon, MD
Associate Director—Pediatric Cancer Immunotherapy Initiative (PCI2)
Assistant Director for Translational Research—UF Health Cancer Center Department of Pediatrics
Division of Hematology/Oncology
University of Florida
June 28, 2025



Disclosures


 I am discussing an investigational agent that is in phase I clinical trials.

CHALLENGES IN PEDIATRIC CANCER IMMUNOTHERAPY


- Diversity of tumors
- Antigenic heterogeneity
- Low mutational burden
- Immunosuppressive TME




Osteosarcoma PM—immune-excluded, tumor-normal lung interface



RNA Lipid nanoparticle aggregate (RNA-LPA): Training the body to recognize cancer




RNA lipid nanoparticle aggregates (RNA-LPA)




By layering mRNA into multi-lamellar nanoparticles we can package more payload for enhanced immunity






https://sergiospizzafactory.com/product/onion/

RNA-NPs reprogram pulmonary OS microenvironment



RNA-nanoparticles activate the immune system QUICKLY in human patients









Title: **RNA** lipid particles targeting **P**ediatric **R**ecurrent **I**ntracranial **M**alignancies and other syst**E**mic solid

tumors

First two cohorts: Relapsed peds high grade glioma (pHGG) and osteosarcoma (OSA)








RNA PRIME: Relapsed Osteosarcoma





Key Inclusion (OSA):

stable neuro status.

- •Age ≤ 39 years
- •For OSA diagnosis of relapse must be histopathologically confirmed following resection/biopsy. Must be eligible for thoracotomy (Arms 1 and 2 only)
- •Washout from prior treatments, in particular no greater than physiologic steroids within 14d of enrollment and
- •ANC>1000, platelets>100,000, Hb>8 (no ALC), and must return to these levels prior to surgery and prior to subsequent vaccines
- Patients with pHGG must be willing to take an antiepileptic medication such as levetiracetam

Translational Studies—Next iterations

Between the UF College of Medicine and College of Veterinary Medicine IACUC approved study evaluating toxicity, efficacy and immunologic responses of RNA-nanoparticle combinations targeting canine brain and osteosarcomas (UF IACUC Protocols: 201609430 and 201710053)—Funded by MIB Agents





Currently testing combination of RNA-LPA + radiation + canine anti-PD-1: 4 dogs living >4 months (median overall survival for canine OSA) without surgical local control or new evidence of disease.



Thank you!



Ligon lab

Xiaojie Ma, PhD

Darrice Montgomery

Cathleen Rabideau

Jesus Mendoza

UF RNA Engineering Lab Members Ji-Hyun Lee, PhD

Elias Savour, MD, PhD Hector Mendez-Gomez, PhD

Frances Weidert, MS, LATG

Dinpeng Zhang, PhD

Nagheme Thomas

Chao Xie, PhD

Emilia Guzman, MD

Omama Ahmad, MD

Rachel Moor, MD

UF Collaborators

Duane Mitchell, MD, PhD

Paul Castillo, MD

Leighton Elliott, MD Christian Jobin, PhD

Ryan Thomas. MD

Rowan Milner, DVM, PhD

Elham Nasri, MD

Tim Foster, MD

Joanne Lagmay, MD

Christina Von Roemeling, PhD

Catherine Flores, PhD

Ashley Ghiaseddin, MD

Giselle Moore-Higgs, PhD Marcia Hodik, RN, CCRC

Kris Wynne, RN, MSHS

PRWCC

Liora Schultz, MD Melody Smith, MD, **PhD**

NPCF Collaborators

Michael Isakoff, MD Lars Wagner, MD

Vivien Yin, PhD

Mas Hayashi, MD

Damon Reed, MD

Gene Hwang, MD

David Kram, MD

Matteo Trucco, MD

Jonathan Metts, MD





V FOUNDATION*

